Current Studies

Home / Current Studies

Enrolling Studies

Study Name Indication Description Stipend Apply
Abbvie M15-554PSA - Psoriatic ArthrtisA Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) Budget amended to enroll up to 20 patients$1015Apply
Abbvie M15-572PSA - Psoriatic ArthrtisA Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab (Humira) in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)$1300Apply
Abbvie M16-063RA - Rheumatoid Arthritis A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599 Combination) With a Background of Conventional Synthetic DMARDs in Subjects With Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs$0Apply
GSK BELIEVELupusA Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety to Belimumab Administered in Combination with Rituximab to Adult Subjects with Systemic Lupus Erythematosus (SLE)$1375Apply
Novartis ASLeapAS - Ankylosing SpondylitisA randomized, double-blind, parallel-group, multicenter study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with Ankylosing Spondylitis who are randomized to dose escalation after not achieving inactive disease during an initial 16 weeks of open-label treatment with secukinumab 150 mg (ASLeap)$0Apply
CREDO 3RA - Rheumatoid ArthritisThe purpose of this study is to determine how safe and effective the study drug Olokizumab is, in patients with Rheumatoid Arthritis (RA) who are already receiving, but not fully responding to treatment with an existing medication called a tumour necrosis factor alpha inhibitor$0Apply
CREDO 2RA - Rheumatoid ArthritisA Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy$0Apply
CREDO 4RA - Rheumatoid ArthritisA Multicenter Open Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severly Active Rheumatoid Arthritis. CREDO 4. Dated 4-28-16 CL04041024$0Apply

Dayton, Ohio has a metropolitan area population of over 800,000 people!

Upcoming Studies

Register

Below is a list of upcoming studies, or medical conditions which we regularly contract studies.  Enrollment periods vary and some studies close enrollment very quickly.  To be notified of new studies, use the registration form to get email or phone updates when new studies become available for conditions which you have.

  • Hypertension (High Blood Pressure)
  • OA - Osteo Arthrtis

Register to receive updates on upcoming studies for which you may qualify for. You may choose to be contacted by phone, text message, or email.